This article is more than 5 years old. Information may no longer be current.

XOMA reports positive additional results for potential treatment for Behçet's uveitis

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

BERKELEY, Calif. — Drug developer XOMA has reported positive supplementary results from an open-label pilot study of a monoclonal antibody when administered as a re-treatment among patients with Behçet's uveitis who received prior immunosuppressive therapy, the company announced in a press release.

The compound, called XOMA 052, which inhibits the inflammatory cytokine interleukin-1 beta, has already received orphan drug designation from both the U.S. Food and Drug Administration and the European Medicines Agency for treating Behçet's disease, the release said.

As previously reported, all seven patients with Behçet's disease experienced rapid reductions in inflammation with improved vision after a single treatment with the compound. These additional results, however, show that each of the five patients re-treated with XOMA 052 due to recurring uveitis exacerbation responded well over several months, with reduced levels of IL-1 beta, IL-1 alpha and IL-6 and encouraging elevations in interferon gamma levels.

XOMA is currently conducting two additional phase 2 clinical trials of XOMA 052 in patients with type 2 and type 1 diabetes, the release said.